GEA Opens a New Chapter for Biopharmaceutical Separation Processes with Pharma Separator Lines Aseptic and Pure

With the introduction of the new separator lines aseptic and pure under the motto "Energizing Pharma", pharmaceutical specialist GEA is ushering in a new era for biopharmaceutical separation processes. Based on GEA's decades of expertise in the field of mechanical separation technology, GEA engineers have developed a new, fully comprehensive portfolio of plug & produce pharma separator systems that moves harmoniously and perfectly between individual and process-related requirements and leaves nothing to be desired. The separator lines aseptic and pure are used in all pharmaceutical and biotechnological downstream processes. GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. The pure line is used in applications with varying hygienic requirements such as nutritional supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery.

 

Perfectly adapted separation solution from GEA

 

The biopharmaceutical industry is united by a common denominator. It places the highest value on uncompromising hygienic design, process reliability and high yield. However, the detailed requirements can vary widely depending on process regulations and specifications. GEA took this requirement profile as an opportunity to develop a separation solution for the biopharmaceutical industry that is perfectly adaptable in every respect.

Development to the highest GEA standards

 

The new pharmaceutical separator lines "aseptic" and "pure" were developed to the highest GEA standards at the German GEA Westfalia Separator plant in Oelde, where they are built and tested. The aseptic line stands for the highest hygienic pharmaceutical requirements. The pure line provides maximum variability and is perfectly tailored to the diverse process requirements of the biopharmaceutical industry. All functions for pharmaceutical cleanliness requirements such as an automatic CIP (Cleaning-in-Place), SIP (Steam Sterilization in Place), simple validation and a high-end qualification package are included. In addition, with the help of the cGMP validation process ("Current Good Manufacturing Practice, cGMP), the pharma separators support GEA customers in their quality standard reviews.

2021.07.06_GEA-Separatoren-aseptic-pure-Photo-2

GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)

 

2021.07.06_GEA-Separatoren-aseptic-pure-Photo-1

Line pure is used in applications with varying hygienic requirements such as dietary supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery. (Photo: GEA)

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

GEA

GEA is one of the world’s largest systems suppliers for the food, beverage and pharmaceutical sectors. The international industrial technology group specializes in machinery and plants as well as advanced process technology, components and comprehensive services. With more than 18,000 employees, the group generated revenue of more than EUR 4.6 billion in fiscal year 2020. A major focus is on continuously enhancing the sustainability and efficiency of customers’ production processes. GEA plants, processes and components help achieve significant reductions in carbon emissions, plastic use and food waste in production worldwide. In this way, GEA makes a decisive contribution toward a sustainable future, fully in line with its corporate philosophy of “engineering for a better world.”

GEA is listed in the German MDAX and the STOXX® Europe 600 Index, and is also among the companies comprising the DAX 50 ESG and MSCI Global Sustainability Indices.

Q: